$AXGN

BofA Securities initiated coverage on AxoGen (NASDAQ:AXGN) with a Buy rating and a $52.00 price target, citing 44% upside potential. The company, a leader in peripheral nerve repair, reported 23.6% revenue growth and a 74.6% gross margin. Near-term catalysts include a prostate market decision and potential coverage expansions. AxoGen recently completed a $208.7 million share offering and acquired BioCircuit, with mixed analyst reactions.

Barclays initiated coverage on Axogen with an Overweight rating and a $55 price target. The rating is based on valuation, EPS revisions, and visibility. Axogen's stock is currently trading at $36.31, down 2.44% over 5 days and 14.44% year-to-date.

Nasdaq Composite gained 0.44% for the week, driven by tech stocks, while Dow Jones and Russell 2000 declined. RTX secured a $24.4B contract, IART lowered FY26 guidance due to flooding, TMQ reported Q3 earnings, PECO increased acquisition guidance, and AXGN completed an acquisition. VIX fell, crude oil dropped, and 10-year Treasury yield rose.

Divisadero Street Capital Management, LP, and related entities reported a 6.8% passive stake in Axogen, Inc., owning 3,983,783 shares. Divisadero Street Partners, L.P., and its general partner reported a 5.9% stake, owning 3,436,008 shares. The shares are directly owned by advisory clients.

Axogen Inc. (AXGN) completed its acquisition of BioCircuit Technologies, a medical device company. BioCircuit's NerveTape is FDA-cleared for nerve repair. Axogen expects BioCircuit to contribute $6M in Q4 2026 and $34M in 2027 revenue, excluding prior guidance. The company maintains its 2026 outlook for 24% revenue growth, 73% gross margin, and positive free cash flow.

Truist Securities reaffirmed a Buy rating on Axogen with a $53 price target, suggesting a 26.4% upside from the Sep 30 close. The firm cited Axogen's strong product portfolio and positive market feedback as key growth drivers.

Truist lowered AxoGen's price target to $53 from $60, citing dilution concerns but maintaining a Buy rating. The firm expects 20%+ annual revenue growth from 2026-2029. AxoGen reported Q2 2026 revenue of $69.7M, up 23% YoY, and a net loss of $1.5M. The company announced a $208.7M public offering. Analysts remain bullish, with a consensus Strong Buy rating.

Axogen, Inc. agreed to acquire BioCircuit Technologies, Inc. for $200 million in cash, expected to close in Q4 2026. BioCircuit's NerveTape™ technology, which simplifies nerve repair, complements Axogen's portfolio. The deal is expected to boost revenue growth, adjusted EBITDA margin, and adjusted earnings per share post-closing, while maintaining positive free cash flow, according to Axogen.

Axogen (AXGN) raised $208.7m via a share offering at $42.50 each, alongside an M&A call. The company's stock is up 36% YTD and 157% over 1 year, but down 13% in the past month. Analysts estimate a fair value of $53.22, highlighting potential undervaluation and growth prospects, but also noting valuation risks and dependence on a single product.

Axogen (AXGN) stock fell 9.0% in pre-market trading after announcing a $200M acquisition of BioCircuit Technologies and a $208.7M equity raise at a 10% discount. The deal includes a 30-day over-allotment option. Axogen expects the acquisition to boost revenue, EBITDA, and earnings. The stock drop is attributed to the discounted equity offering.